MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-06-2026
Biogen Net Debt 2011-2026 | BIIB
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Biogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 B | -1.95 B | -560 M | 2.96 B | 4.1 B | 6.1 B | 3.04 B | 7.03 B | 4.36 B | 4.19 B | 5.22 B | -620 M | -6.66 M | 570 M | 550 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.03 B | -1.95 B | 2.56 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burford Capital Limited
BUR
|
-135 M | $ 4.81 | 2.02 % | $ 761 M |  Britain |
 |
Cabaletta Bio
CABA
|
-76.6 M | $ 3.37 | 3.45 % | $ 339 M |  USA |
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.2 | 4.75 % | $ 5.27 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 334.86 | -1.34 % | $ 43.9 B | USA |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.73 | 3.04 % | $ 8.97 B |  Australia |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-132 M | $ 7.36 | -15.79 % | $ 72.8 M | USA |
 |
Esperion Therapeutics
ESPR
|
-165 M | $ 2.08 | 1.22 % | $ 432 M | USA |
 |
Evogene Ltd.
EVGN
|
-3.44 M | $ 0.86 | 4.76 % | $ 27.9 M | Israel |
 |
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | USA |
 |
Forte Biosciences
FBRX
|
-58.8 M | $ 31.11 | -4.04 % | $ 403 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
-1.29 B | $ 29.11 | 0.8 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
-6.94 B | $ 29.26 | 0.67 % | $ 18.8 B |  Danmark |
 |
GT Biopharma
GTBP
|
-5.5 M | $ 0.38 | -1.83 % | $ 2.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 21.69 | 1.45 % | $ 1.01 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
-608 M | $ 29.22 | -0.24 % | $ 1.68 B | USA |
 |
BioNTech SE
BNTX
|
-973 M | $ 99.83 | 1.44 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
3.77 M | $ 7.64 | -1.18 % | $ 69 M | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
InflaRx N.V.
IFRX
|
-32.3 M | $ 1.21 | 6.14 % | $ 152 M | Germany |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-133 M | $ 1.54 | -1.23 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.19 | 1.07 % | $ 448 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.26 | -3.31 % | $ 3.09 B | USA |
 |
Incyte Corporation
INCY
|
-3.06 B | $ 97.7 | 0.01 % | $ 19.1 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Innate Pharma S.A.
IPHA
|
-120 M | $ 1.66 | 1.57 % | $ 235 M | France |
 |
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.48 | -0.34 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B |  Cayman-islands |